CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
serum aquaporin 4 antibody (AQP-4-Ab) +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03819413
NCT03819413N/ACompleted

Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital

Assiut University·observational·Posted Jan 28, 2019·Updated Nov 6, 2020

In Brief

An observational study evaluating serum aquaporin 4 antibody (AQP-4-Ab), serum MOG antibody (anti-MOG), and 1 other intervention for Neuromyelitis Optica Spectrum Disorder. Completed, enrolled 90 participants across 1 site.

Detailed Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) are a group of inflammatory demyelinating disorders of the central nervous system. Although NMOSD occurs much more commonly in nations with a predominately non-Caucasian population, NMOSD are underestimated in Egypt and frequently misdiagnosed as multiple sclerosis (MS). In this study, by investigating serum anti-aquaporin (AQP) 4 and anti-MOG antibody of patients suspected to have NMOSD attending the Neurology and Psychiatry department of Assiut University Hospital, investigators aim to determine the relative frequency, clinical and radiological characteristics of NMOSD in upper Egypt community and compare it with other populations of different races.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 28, 2019
Enrollment StartFeb 15, 2019
Primary CompletionJul 15, 2020
Study CompletionAug 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.4 years ago

Interventions

serum aquaporin 4 antibody (AQP-4-Ab)other

All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)

serum MOG antibody (anti-MOG)other

All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)

MRI brain, spine and orbitother

All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium